The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

@article{Maiso2006TheHD,
  title={The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.},
  author={Patricia Maiso and Xonia Carvajal-Vergara and Enrique Mar{\'i}a Ocio and Ricardo L{\'o}pez-P{\'e}rez and Gema Mateo and Norma Guti{\'e}rrez and Peter W Atadja and Atanasio Pandiella and Jes{\'u}s Fernando San Miguel},
  journal={Cancer research},
  year={2006},
  volume={66 11},
  pages={5781-9}
}
Multiple myeloma represents an incurable disease, for which development of new therapies is required. Here, we report the effect on myeloma cells of LBH589, a new hydroxamic acid-derived histone deacetylase inhibitor. LBH589 was a potent antimyeloma agent (IC(50) < 40 nmol/L) on both cell lines and fresh cells from multiple myeloma patients, including cells resistant to conventional chemotherapeutic agents. In addition, LBH589 potentiated the action of drugs, such as bortezomib, dexamethasone… CONTINUE READING
112 Citations
34 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 112 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Similar Papers

Loading similar papers…